14 November 2007 - Medical Marketing International Group plc ('MMI' or the 'Company') (AIM:MMG), the pharmaceutical company focused on the development of drugs for cancer and infectious diseases, today announces that it has reached agreement with its partners, King's College London (KCL), Queen Mary University of London (QMUL) and the inventing scientists, for an option to acquire their shareholdings in Viratis, MMI's subsidiary which is developing HIV and Hepatitis B therapies based on gene silencing.
